Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
RIGL's Cash-to-Debt is ranked higher than
99% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. RIGL: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RIGL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.76  Med: 61.9 Max: No Debt
Current: No Debt
Equity-to-Asset 0.70
RIGL's Equity-to-Asset is ranked higher than
64% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. RIGL: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
RIGL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.04  Med: 0.74 Max: 0.93
Current: 0.7
0.04
0.93
Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
99% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.29 vs. RIGL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RIGL' s Interest Coverage Range Over the Past 10 Years
Min: 388.1  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 1
Altman Z-Score: -11.89
Beneish M-Score: -3.36
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -342.15
RIGL's Operating Margin % is ranked lower than
92% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. RIGL: -342.15 )
Ranked among companies with meaningful Operating Margin % only.
RIGL' s Operating Margin % Range Over the Past 10 Years
Min: -14938.27  Med: -1106.05 Max: 28.25
Current: -342.15
-14938.27
28.25
Net Margin % -339.58
RIGL's Net Margin % is ranked lower than
91% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. RIGL: -339.58 )
Ranked among companies with meaningful Net Margin % only.
RIGL' s Net Margin % Range Over the Past 10 Years
Min: -14872.93  Med: -1101.92 Max: 30.31
Current: -339.58
-14872.93
30.31
ROE % -95.73
RIGL's ROE % is ranked lower than
92% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. RIGL: -95.73 )
Ranked among companies with meaningful ROE % only.
RIGL' s ROE % Range Over the Past 10 Years
Min: -142.04  Med: -50.45 Max: 27.46
Current: -95.73
-142.04
27.46
ROA % -68.38
RIGL's ROA % is ranked lower than
92% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. RIGL: -68.38 )
Ranked among companies with meaningful ROA % only.
RIGL' s ROA % Range Over the Past 10 Years
Min: -101.94  Med: -43.28 Max: 23.14
Current: -68.38
-101.94
23.14
ROC (Joel Greenblatt) % -4807.07
RIGL's ROC (Joel Greenblatt) % is ranked lower than
95% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. RIGL: -4807.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RIGL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5037.27  Med: -2565.59 Max: 1113
Current: -4807.07
-5037.27
1113
3-Year Revenue Growth Rate 38.10
RIGL's 3-Year Revenue Growth Rate is ranked higher than
93% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. RIGL: 38.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RIGL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -37.9 Max: 121.7
Current: 38.1
0
121.7
3-Year EBITDA Growth Rate -9.80
RIGL's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. RIGL: -9.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RIGL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47  Med: -21.7 Max: 23.2
Current: -9.8
-47
23.2
3-Year EPS without NRI Growth Rate -10.60
RIGL's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. RIGL: -10.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RIGL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.5  Med: -21.5 Max: 21.8
Current: -10.6
-56.5
21.8
GuruFocus has detected 4 Warning Signs with Rigel Pharmaceuticals Inc $RIGL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RIGL's 10-Y Financials

Financials (Next Earnings Date: 2017-06-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RIGL Guru Trades in Q1 2016

John Paulson 999,700 sh (+89.09%)
Paul Tudor Jones 29,251 sh (+38.54%)
Jim Simons 660,800 sh (+32.27%)
Charles Brandes Sold Out
» More
Q2 2016

RIGL Guru Trades in Q2 2016

Jim Simons 792,600 sh (+19.95%)
John Paulson 999,700 sh (unchged)
Paul Tudor Jones 29,251 sh (unchged)
» More
Q3 2016

RIGL Guru Trades in Q3 2016

Paul Tudor Jones 42,241 sh (+44.41%)
John Paulson 805,000 sh (-19.48%)
Jim Simons 629,800 sh (-20.54%)
» More
Q4 2016

RIGL Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Jim Simons Sold Out
John Paulson 387,697 sh (-51.84%)
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:TTPH, NAS:ZYNE, NAS:ADMS, NAS:AQXP, NAS:SNDX, NAS:KPTI, OTCPK:MQTRF, NAS:COLL, NAS:ACET, OTCPK:CURR, NAS:SCMP, NAS:SCLN, NAS:INNL, OTCPK:CMMDF, NAS:LBIO, OTCPK:ACBFF, OTCPK:OWCP, NAS:NEOS, NAS:SMMT, OTCPK:OGRMF » details
Traded in other countries:RI2A.Germany,
Rigel Pharmaceuticals Inc is a clinical-stage drug development company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.

Rigel Pharmaceuticals develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken over all responsibility to develop and market the drug and will pay Rigel royalties and milestone payments.

Ratios

vs
industry
vs
history
PB Ratio 5.00
RIGL's PB Ratio is ranked lower than
71% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. RIGL: 5.00 )
Ranked among companies with meaningful PB Ratio only.
RIGL' s PB Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.61 Max: 10.47
Current: 5
1.02
10.47
PS Ratio 12.58
RIGL's PS Ratio is ranked lower than
84% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. RIGL: 12.58 )
Ranked among companies with meaningful PS Ratio only.
RIGL' s PS Ratio Range Over the Past 10 Years
Min: 2.8  Med: 28.17 Max: 543.89
Current: 12.58
2.8
543.89
Current Ratio 3.37
RIGL's Current Ratio is ranked higher than
66% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. RIGL: 3.37 )
Ranked among companies with meaningful Current Ratio only.
RIGL' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.65 Max: 24.78
Current: 3.37
0.9
24.78
Quick Ratio 3.37
RIGL's Quick Ratio is ranked higher than
73% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. RIGL: 3.37 )
Ranked among companies with meaningful Quick Ratio only.
RIGL' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 6.65 Max: 24.78
Current: 3.37
0.9
24.78

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.30
RIGL's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. RIGL: -4.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RIGL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153.2  Med: -18.8 Max: -1.3
Current: -4.3
-153.2
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.33
RIGL's Price-to-Net-Cash is ranked higher than
66% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.69 vs. RIGL: 5.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RIGL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.28  Med: 3.8 Max: 11.01
Current: 5.33
1.28
11.01
Price-to-Net-Current-Asset-Value 5.23
RIGL's Price-to-Net-Current-Asset-Value is ranked higher than
64% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. RIGL: 5.23 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RIGL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.23  Med: 3.09 Max: 10.28
Current: 5.23
1.23
10.28
Price-to-Tangible-Book 5.04
RIGL's Price-to-Tangible-Book is ranked lower than
63% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. RIGL: 5.04 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RIGL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 3 Max: 9.69
Current: 5.04
1.2
9.69
Price-to-Median-PS-Value 0.45
RIGL's Price-to-Median-PS-Value is ranked higher than
93% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. RIGL: 0.45 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RIGL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 0.41 Max: 18.65
Current: 0.45
0.09
18.65
Earnings Yield (Greenblatt) % -26.42
RIGL's Earnings Yield (Greenblatt) % is ranked lower than
89% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. RIGL: -26.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RIGL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -27.05  Med: 15.5 Max: 6128.3
Current: -26.42
-27.05
6128.3

More Statistics

Revenue (TTM) (Mil) $20.38
EPS (TTM) $ -0.73
Beta1.27
Short Percentage of Float4.49%
52-Week Range $1.90 - 4.38
Shares Outstanding (Mil)99.27

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 31 64 66
EPS ($) -0.37 -0.09 -0.11
EPS without NRI ($) -0.37 -0.09 -0.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RIGL

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
5 Cheap Breakout Stocks for Superb Returns Mar 16 2017
RIGEL PHARMACEUTICALS INC Financials Mar 11 2017
Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 Mar 09 2017
Edited Transcript of RIGL earnings conference call or presentation 7-Mar-17 10:00pm GMT Mar 08 2017
Rigel reports 4Q loss Mar 07 2017
Rigel reports 4Q loss Mar 07 2017
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 07 2017
Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update Mar 07 2017
Q4 2016 Rigel Pharmaceuticals Inc Earnings Release - After Market Close Mar 07 2017
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial... Feb 28 2017
[2/23] Today's Top 10 Long/Short Estimize Signal Scores Feb 23 2017
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Feb 08 2017
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase... Feb 03 2017
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 31 2017
Rigel Announces Pricing Of Public Offering Of Common Stock Jan 31 2017
RIGEL PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Jan 30 2017
Rigel Announces Proposed Public Offering Of Common Stock Jan 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)